Analyst Price Targets — RGNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 1, 2026 11:00 am | Yi Chen | H.C. Wainwright | $26.00 | $11.98 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX) |
| June 22, 2026 2:21 pm | Mani Foroohar | Leerink Partners | $18.00 | $8.88 | StreetInsider | Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink |
| June 22, 2026 1:50 pm | Brian Skorney | Robert W. Baird | $32.00 | $8.91 | StreetInsider | Regenxbio Inc. (RGNX) PT Raised to $32 at Baird |
| May 15, 2026 12:29 pm | — | Morgan Stanley | $16.00 | $6.31 | TheFly | Regenxbio price target lowered to $16 from $17 at Morgan Stanley |
| May 15, 2026 9:00 am | Eliana Merle | Barclays | $12.00 | $6.25 | TheFly | Regenxbio price target lowered to $12 from $37 at Barclays |
| March 9, 2026 10:13 am | — | H.C. Wainwright | $30.00 | $10.38 | TheFly | Regenxbio price target lowered to $30 from $32 at H.C. Wainwright |
| March 5, 2026 7:52 pm | Judah Frommer | Morgan Stanley | $17.00 | $8.72 | StreetInsider | Regenxbio Inc. (RGNX) PT Lowered to $17 at Morgan Stanley |
| February 10, 2026 2:05 pm | — | H.C. Wainwright | $32.00 | $8.92 | TheFly | Regenxbio price target lowered to $32 from $34 at H.C. Wainwright |
| February 10, 2026 1:50 pm | Brian Skorney | Robert W. Baird | $27.00 | $8.92 | TheFly | Regenxbio price target lowered to $27 from $39 at Baird |
| February 10, 2026 1:35 pm | — | UBS | $18.00 | $8.97 | TheFly | Regenxbio price target lowered to $18 from $25 at Morgan Stanley |
Latest News for RGNX
One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids Prevention of vision-threatening events without any additional…
ROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discounts and commissions.
ROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering.
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders.
New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026 ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RGNX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.